ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims

The complaint alleges that ADMA Biologics misled shareholders by concealing a related party transaction and utilizing channel stuffing to artificially inflate revenue figures. According to court filings, the company purportedly lacked the internal controls necessary to ensure the accuracy of its financial reporting. These omissions allegedly rendered the firm's positive public statements regarding its operations and business health materially deceptive.

Shareholders who purchased ADMA stock during the class period and suffered losses are eligible to participate in the legal proceedings. While investors do not need to take immediate action to remain members of the class, those seeking to serve as lead plaintiffs must contact the Law Offices of Howard G. Smith before the August deadline. The firm is reachable at 215-638-4847 or via their website for those inquiring about their legal rights or the specifics of the ongoing case.